Shanghai - Jacos Pharmaceuticals (1167.HK) announced a clinical collaboration with Merck (Merk & Co., Inc., Lowe, New Jersey, USA) to evaluate The combination therapy of Si's CD73 monoclonal antibody JAB-BX102 and Merck's PD-1 inhibitor KEYTRUDA (pembrolizumab).

This clinical study will evaluate the clinical effect of JAB-BX102 in combination with KEYTRUDA in advanced solid tumors. Under the terms of the agreement, Merck will provide KEYTRUDA.

Dr. Wang Yinxiang, chairman and CEO of JACOS, pointed out: 'CD73 is the first macromolecule project of JACOS to enter the clinical stage. As an important target in the tumor immune pathway, we believe that CD73 and the same tumor immune pathway Combination trials with PD-1 inhibitors have the potential to relieve the immunosuppression of the tumor microenvironment, stimulate the proliferation and activation of killer immune cells, and enhance tumor immunity. We look forward to exploring the combination of CD73 monoclonal antibody and anti-cancer drug through this cooperation with Merck. The potential utility of PD-1 in tumor immunotherapy is also expected to bring new treatment options to patients.'

KEYTRUDA is a registered trademark owned by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Lowe, NJ, USA.

About JAB-BX102

JAB-BX102 is a CD73 humanized monoclonal antibody independently developed by Jacos. It has obtained clinical approval for new drugs from the US FDA and China CDE in October 2021 and March 2022, respectively. JAB-BX102 has currently launched Phase I/IIa of JAB-BX102 monotherapy and in combination with pembrolizumab in advanced solid tumors in China and the United States for safety, tolerability, pharmacokinetics and preliminary anti-tumor efficacy , multicenter, open research. The currently published clinical data show that the combination of CD73 monoclonal antibody and PD-(L)1 monoclonal antibody can significantly prolong the survival of patients with non-small cell lung cancer.

About JACOS

Jacobs Pharmaceuticals (1167.HK) is committed to providing patients with breakthrough treatment solutions. The company's ongoing research projects focus on the six major tumor signaling pathways of KRAS, tumor immunity, tumor metabolism, P53, RB, and MYC, and the core projects target the top three in the world. The company's vision is to work hand in hand with partners to become a globally recognized leader in drug development. Jacobs' laboratories are located in Beijing, Shanghai, China, and Boston, USA, with an induced allosteric drug discovery platform and an iADC drug development platform.

Contact:

Email: ir@jacobiopharma.com

Tel: 010-56315466-8049

(C) 2023 Electronic News Publishing, source ENP Newswire